176 related articles for article (PubMed ID: 36799021)
41. Characterization of the major single nucleotide polymorphic variants of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase).
Detlefsen AJ; Wangtrakuldee P; Penning TM
J Steroid Biochem Mol Biol; 2022 Jul; 221():106121. PubMed ID: 35489629
[TBL] [Abstract][Full Text] [Related]
42. Source and amount of carbohydrate in the diet and inflammation in women with polycystic ovary syndrome.
Barrea L; Marzullo P; Muscogiuri G; Di Somma C; Scacchi M; Orio F; Aimaretti G; Colao A; Savastano S
Nutr Res Rev; 2018 Dec; 31(2):291-301. PubMed ID: 30033891
[TBL] [Abstract][Full Text] [Related]
43. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Liu C; Armstrong CM; Lou W; Lombard A; Evans CP; Gao AC
Mol Cancer Ther; 2017 Jan; 16(1):35-44. PubMed ID: 27794047
[TBL] [Abstract][Full Text] [Related]
45. Androgens drive microvascular endothelial dysfunction in women with polycystic ovary syndrome: role of the endothelin B receptor.
Usselman CW; Yarovinsky TO; Steele FE; Leone CA; Taylor HS; Bender JR; Stachenfeld NS
J Physiol; 2019 Jun; 597(11):2853-2865. PubMed ID: 30847930
[TBL] [Abstract][Full Text] [Related]
46. 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.
O'Reilly MW; Kempegowda P; Jenkinson C; Taylor AE; Quanson JL; Storbeck KH; Arlt W
J Clin Endocrinol Metab; 2017 Mar; 102(3):840-848. PubMed ID: 27901631
[TBL] [Abstract][Full Text] [Related]
47. Discovery of Novel Lipid Profiles in PCOS: Do Insulin and Androgen Oppositely Regulate Bioactive Lipid Production?
Li S; Chu Q; Ma J; Sun Y; Tao T; Huang R; Liao Y; Yue J; Zheng J; Wang L; Xue X; Zhu M; Kang X; Yin H; Liu W
J Clin Endocrinol Metab; 2017 Mar; 102(3):810-821. PubMed ID: 27886515
[TBL] [Abstract][Full Text] [Related]
48. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Zeng X; Xie YJ; Liu YT; Long SL; Mo ZC
Clin Chim Acta; 2020 Mar; 502():214-221. PubMed ID: 31733195
[TBL] [Abstract][Full Text] [Related]
49. Dynamic changes in chromatin accessibility, altered adipogenic gene expression, and total versus de novo fatty acid synthesis in subcutaneous adipose stem cells of normal-weight polycystic ovary syndrome (PCOS) women during adipogenesis: evidence of cellular programming.
Leung KL; Sanchita S; Pham CT; Davis BA; Okhovat M; Ding X; Dumesic P; Grogan TR; Williams KJ; Morselli M; Ma F; Carbone L; Li X; Pellegrini M; Dumesic DA; Chazenbalk GD
Clin Epigenetics; 2020 Nov; 12(1):181. PubMed ID: 33228780
[TBL] [Abstract][Full Text] [Related]
50. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
[TBL] [Abstract][Full Text] [Related]
51. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies.
Li M; Zhang L; Yu J; Wang X; Cheng L; Ma Z; Chen X; Wang L; Goh BC
Front Pharmacol; 2024; 15():1378292. PubMed ID: 38523637
[TBL] [Abstract][Full Text] [Related]
52. Androgens in polycystic ovary syndrome: the role of exercise and diet.
Giallauria F; Palomba S; Vigorito C; Tafuri MG; Colao A; Lombardi G; Orio F
Semin Reprod Med; 2009 Jul; 27(4):306-15. PubMed ID: 19530064
[TBL] [Abstract][Full Text] [Related]
53. The therapeutic effect of interleukin-22 in high androgen-induced polycystic ovary syndrome.
Qi X; Yun C; Liao B; Qiao J; Pang Y
J Endocrinol; 2020 May; 245(2):281-289. PubMed ID: 32163914
[TBL] [Abstract][Full Text] [Related]
54. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Liu C; Yang JC; Armstrong CM; Lou W; Liu L; Qiu X; Zou B; Lombard AP; D'Abronzo LS; Evans CP; Gao AC
Mol Cancer Ther; 2019 Oct; 18(10):1875-1886. PubMed ID: 31308078
[TBL] [Abstract][Full Text] [Related]
55. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization.
Caldwell AS; Eid S; Kay CR; Jimenez M; McMahon AC; Desai R; Allan CM; Smith JT; Handelsman DJ; Walters KA
Endocrinology; 2015 Apr; 156(4):1441-52. PubMed ID: 25643156
[TBL] [Abstract][Full Text] [Related]
56. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy.
Wu C; Dai C; Li X; Sun M; Chu H; Xuan Q; Yin Y; Fang C; Yang F; Jiang Z; Lv Q; He K; Qu Y; Zhao B; Cai K; Zhang S; Sun R; Xu G; Zhang L; Sun S; Liu Y
Theranostics; 2022; 12(18):7681-7698. PubMed ID: 36451864
[No Abstract] [Full Text] [Related]
57. Decreased brain and muscle ARNT-like protein 1 expression mediated the contribution of hyperandrogenism to insulin resistance in polycystic ovary syndrome.
Zhai J; Li S; Hu M; Di F; Liu J; Du Y
Reprod Biol Endocrinol; 2020 Apr; 18(1):32. PubMed ID: 32334629
[TBL] [Abstract][Full Text] [Related]
58. CAG repeat polymorphism in androgen receptor gene is not directly associated with polycystic ovary syndrome but influences serum testosterone levels.
Skrgatic L; Baldani DP; Cerne JZ; Ferk P; Gersak K
J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):107-12. PubMed ID: 22107839
[TBL] [Abstract][Full Text] [Related]
59. Is foetal hyperexposure to androgens a cause of PCOS?
Filippou P; Homburg R
Hum Reprod Update; 2017 Jul; 23(4):421-432. PubMed ID: 28531286
[TBL] [Abstract][Full Text] [Related]
60. Polycystic ovary syndrome in the pediatric population.
Bremer AA
Metab Syndr Relat Disord; 2010 Oct; 8(5):375-94. PubMed ID: 20939704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
